中医药干预溃疡性结肠炎及与硬脂酰辅酶A脱氢酶1（SCD-1）的相关性研究

发布时间：2018-04-27 05:03

本文选题：硬脂酰辅酶A脱氢酶1 + 硬脂酰溶血卵磷脂　；参考：《南京中医药大学》2016年硕士论文

【摘要】：目的：运用代谢组学研究溃疡性结肠炎(Ulcerative Colitis, UC)患者与健康人群之间硬脂酰辅酶A脱氢酶1 (Stearoyl-CoA desaturase1, SCD-1)(硬脂酰溶血卵磷脂和油酰溶血溶血卵磷脂比值)的关系,同时观察中医药联合基础治疗后UC患者体内SCD-1变化规律,进一步探索溃疡性结肠炎与人体脂质代谢之间的密切联系,以期寻求新的诊断标准,实现早期发现、早期治疗、提高生活质量的理念。方法：收集51例血清样本(15例健康志愿者和18例轻度、中度脾虚湿盛型治疗前后的UC患者),用液相色谱-质谱检测硬脂酰溶血卵磷脂(Stearoyl Lysophosphatidylcholine,硬脂酰-LPC)和油酰溶血卵磷脂(Oleoyl Lysophosphatidylcholine,油酰-LPC)的比值。同时将不同分组检查指标白细胞计数(WBC)、C-反应蛋白(CRP)、血沉(ESR)以及Mayo评分进行分析,治疗上参苓白术散加减联合艾迪莎(轻度组为2∥日,中度组则为3∥日,法国爱的发制药集团,注册证号：H20100062)和美常安(轻度组为250mg/日,中度组为500mg/日,北京韩美公司生产)。准确记录健康志愿者和UC患者治疗前后相关指标的变化,采集的全部数据使用SPSS20.0软件建立数据库,统计方法使用t检验和单因素方差分析,数据不符合正态分布的则采用Wilcoxon秩和检验等其它方法。结论及意义：两组轻、中度患者治疗前后均未出现明显的不良反应。三组在年龄、性别方面经X2检验为P0.05,差异无统计学意义,硬脂酰-LPC与油酰-LPC的比值治疗前经方差分析P0.05,差异有统计学意义,均数比较：正常组轻度组中度组；治疗后P=0.1010.05,差异无统计学意义。轻度组、中度组在治疗前后WBC、ESR、CRP、Mayo评分均有好转(P0.05)。通过临床血清标本检测,SCD-1与UC的病情严重程度呈负相关性,通过治疗后Mayo评分、常规炎性指标有所下降,可能由于治疗时间偏短和各种干扰因素,患者SCD-1变化不太明显。通过对SCD-1的研究,为UC带来新的的诊断标准,以期早期治疗,提高患者生活治疗。
[Abstract]:Objective: to study the relationship between stearyl coenzyme A dehydrogenase 1 Stearoyl-CoA desaturase1 (SCD-1) and the ratio of stearyl lysozyme lecithin and oleyl lysophosphatidylcholine between patients with ulcerative colitis (UCC) and healthy controls. At the same time, we observed the changes of SCD-1 in patients with UC after the combination of traditional Chinese medicine and basic therapy, and further explored the close relationship between ulcerative colitis and human lipid metabolism in order to seek new diagnostic criteria for early detection and early treatment. The idea of improving the quality of life. Methods: 51 serum samples were collected from 15 healthy volunteers and 18 mild volunteers. The ratio of Stearoyl Lysophosphatidylcholine (Stearoyl Lysophosphatidylcholine) and Oleoyl Lysophosphatidylcholine (Oleoyl Lysophosphatidylcholine) was measured by liquid chromatography-mass spectrometry. At the same time, the white blood cell count (WBC) and erythrocyte sedimentation rate (ESR) and Mayo score were analyzed in different groups. The patients were treated with Shangshenling Atractylodes Powder plus or minus Adiesa (2 / d in the mild group and 3 / 12 / d in the moderate group). France Ailfa Pharmaceutical Group, registration No.: H20100062) and Meichang'an (mild group is 250mg/ day, moderate group is 500mg/ day), Beijing Korea and American companies produce. The changes of related indexes of healthy volunteers and UC patients before and after treatment were recorded accurately. All the data collected were established by SPSS20.0 software. The statistical methods were t test and single factor analysis of variance (ANOVA). Other methods, such as Wilcoxon rank sum test, are used for those whose data do not conform to normal distribution. Conclusion and significance: there were no significant adverse reactions before and after treatment in mild and moderate patients. The age and sex of the three groups were examined by X2 test (P0.05), the difference was not statistically significant. The ratio of stearyl LPC to oleyl LPC was analyzed by ANOVA before treatment (P0.05). After treatment, there was no significant difference between the two groups (P < 0. 1010.05). In mild group and moderate group, the scores of ESR and CRP Mayo were improved before and after treatment (P 0.05). The clinical serum samples showed a negative correlation with the severity of UC. After treatment, the Mayo score showed a decrease in the routine inflammatory indexes. It was possible that the changes of SCD-1 were not obvious due to the short duration of treatment and various interfering factors. Through the study of SCD-1, a new diagnostic standard for UC is brought forward, in order to treat early and improve the life of the patients.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】